Low Rate of Drug Discontinuation, Frequent Need for Dose Adjustment, and No Association with Development of New Arthralgia in Patients Treated with Vedolizumab: Results from a Tertiary Referral IBD Center

[11] Sinagra E(2001)The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study Am J Gastroenterol 96 1116-1122

[12] Perricone G(2016)Paradoxical articular manifestations in patients with inflammatory bowel diseases treated with infliximab Eur J Gastroenterol Hepatol 28 876-881

[13] Romano C(2017)An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease: a case series Ann Rheum Dis 76 878-881

[14] Lichtenstein GR(2018)The association between arthralgia and vedolizumab using natural language processing Inflamm Bowel Dis 24 2242-2246

[15] Feagan BG(2019)Incidence of arthritis/arthralgia in inflammatory bowel disease with long-term vedolizumab treatment: post hoc analyses of the GEMINI trials J Crohns Colitis 13 50-57

[16] Cohen RD(2018)Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort Aliment Pharmacol Ther 47 485-493

[17] Sandborn WJ(1998)Enrichment of T cells carrying beta7 integrins in inflamed synovial tissue from patients with early spondyloarthropathy, compared to rheumatoid arthritis J Rheumatol 25 1932-1937

[18] Feagan BG(2008)Use of the noninvasive components of the mayo score to assess clinical response in ulcerative colitis Inflamm Bowel Dis 14 1660-1666

[19] Rutgeerts P(2010)Correlation between the Crohn’s disease activity and Harvey–Bradshaw indices in assessing Crohn’s disease severity Clin Gastroenterol Hepatol 8 357-363

[20] Feagan BG(2013)Validation of endoscopic activity scores in patients with Crohn’s disease based on a post hoc analysis of data from SONIC Gastroenterology 145 978-986

[11] Sinagra E(2001)The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study Am J Gastroenterol 96 1116-1122

[12] Perricone G(2016)Paradoxical articular manifestations in patients with inflammatory bowel diseases treated with infliximab Eur J Gastroenterol Hepatol 28 876-881

[13] Romano C(2017)An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease: a case series Ann Rheum Dis 76 878-881

[14] Lichtenstein GR(2018)The association between arthralgia and vedolizumab using natural language processing Inflamm Bowel Dis 24 2242-2246

[15] Feagan BG(2019)Incidence of arthritis/arthralgia in inflammatory bowel disease with long-term vedolizumab treatment: post hoc analyses of the GEMINI trials J Crohns Colitis 13 50-57

[16] Cohen RD(2018)Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort Aliment Pharmacol Ther 47 485-493

[17] Sandborn WJ(1998)Enrichment of T cells carrying beta7 integrins in inflamed synovial tissue from patients with early spondyloarthropathy, compared to rheumatoid arthritis J Rheumatol 25 1932-1937

[18] Feagan BG(2008)Use of the noninvasive components of the mayo score to assess clinical response in ulcerative colitis Inflamm Bowel Dis 14 1660-1666

[19] Rutgeerts P(2010)Correlation between the Crohn’s disease activity and Harvey–Bradshaw indices in assessing Crohn’s disease severity Clin Gastroenterol Hepatol 8 357-363

[20] Feagan BG(2013)Validation of endoscopic activity scores in patients with Crohn’s disease based on a post hoc analysis of data from SONIC Gastroenterology 145 978-986